Para acceder a los documentos con el texto completo, por favor, siga el siguiente enlace: http://hdl.handle.net/2445/116351
dc.contributor.author | Stanzani, Elisabetta |
---|---|
dc.contributor.author | Martínez Soler, Fina |
dc.contributor.author | Martín Mateos, Teresa |
dc.contributor.author | Vidal, Noemí |
dc.contributor.author | Villanueva Garatachea, Alberto |
dc.contributor.author | Pujana Genestar, M. Ángel |
dc.contributor.author | Serra-Musach, Jordi |
dc.contributor.author | Iglesia, Núria de la |
dc.contributor.author | Giménez Bonafé, Pepita |
dc.contributor.author | Tortosa i Moreno, Avelina |
dc.date | 2017-10-09T12:13:55Z |
dc.date | 2017-10-09T12:13:55Z |
dc.date | 2017-09 |
dc.date | 2017-10-09T12:13:55Z |
dc.identifier | 1949-2553 |
dc.identifier | 671378 |
dc.identifier | 29088733 |
dc.identifier.uri | http://hdl.handle.net/2445/116351 |
dc.description | Glioblastoma (GBM) still remains an incurable disease being radiotherapy (RT) the mainstay treatment. Glioblastoma intra-tumoral heterogeneity and GlioblastomaInitiating Cells (GICs) challenge the design of effective therapies. We investigated GICs and non-GICs response to RT in a paired in-vitro model and addressed molecular programs activated in GICs after RT. Established GICs heterogeneously expressed several GICs markers and displayed a mesenchymal signature. Upon fractionated RT, GICs reported higher radioresistance compared to non-GICs and showed lower α- and β-values, according to the Linear Quadratic Model interpretation of the survival curves. Moreover, a significant correlation was observed between GICs radiosensitivity and patient disease-free survival. Transcriptome analysis of GICs after acquisition of a radioresistant phenotype reported significant activation of Proneural-to-Mesenchymal transition (PMT) and pro-inflammatory pathways, being STAT3 and IL6 the major players. Our findings support a leading role of mesenchymal GICs in defining patient response to RT and provide the grounds for targeted therapies based on the blockade of inflammatory pathways to overcome GBM radioresistance. |
dc.format | 14 p. |
dc.format | application/pdf |
dc.language | eng |
dc.publisher | Impact Journals |
dc.relation | Reproducció del document publicat a: https://doi.org/10.18632/oncotarget.18363 |
dc.relation | Oncotarget, 2017, vol. 8, num. 43, p. 73640-73653 |
dc.relation | https://doi.org/10.18632/oncotarget.18363 |
dc.rights | cc-by (c) Stanzani, Elisabetta et al., 2017 |
dc.rights | http://creativecommons.org/licenses/by/3.0/es |
dc.rights | info:eu-repo/semantics/openAccess |
dc.subject | Glioma |
dc.subject | Tumors cerebrals |
dc.subject | Cèl·lules mare |
dc.subject | Resistència als medicaments |
dc.subject | Radioteràpia |
dc.subject | Gliomas |
dc.subject | Brain tumors |
dc.subject | Stem cells |
dc.subject | Drug resistance |
dc.subject | Radiotherapy |
dc.title | Radioresistance of mesenchymal glioblastoma initiating cells correlates with patient outcome and is associated with activation of inflammatory program |
dc.type | info:eu-repo/semantics/article |
dc.type | info:eu-repo/semantics/publishedVersion |